Compensation award — excluded from discretionary-purchase analysis.
Written from the filing's own figures. OQRO describes what was reported and never tells you what to buy or sell
View the official recordSEC Form 4 — Statement of Changes in Beneficial OwnershipAll the details
Dates, kept separate
Transaction date
Dec 12, 2025
Reporting period
Not applicable
Filed with the SEC
Dec 16, 2025
CEOGrant / award
Context
Classification
grant award
Code A — grant or award
Planned / mechanical clue
Footnote references vesting of compensation awards
Only flagged when a footnote says so; never inferred
Source receipt
Record ID
0001423029-25-000003
Filed / recorded
Dec 16, 2025, 6:14 PM UTC
Added to OQRO
Oct 6, 2026, 4:40 PM UTC
Parser
form4-xml-v2
Data quality
Verified: identifiers matched exactly
Issuer
ARROWHEAD PHARMACEUTICALS, INC.
Issuer CIK
879407
Ticker
ARWR
Reporting person
Christopher Richard Anzalone
Relationship
Director, Officer
Officer title
Chief Executive Officer
Security
Common Stock
Table
Non-derivative (Table I)
Transaction date
Dec 12, 2025
Transaction code
A
Shares / units
180,000
Price per share
$0.00
Acquired / disposed
Acquired (A)
Shares owned after
4,101,255
Ownership form
Direct
Amendment
No
Footnotes from the filing
Represents shares underlying restricted stock units with a grant date December 12, 2025, which will vest in four equal annual installments.
Includes previously reported shares of common stock underlying Restricted Stock Units granted to the Reporting person, a portion of which are still subject to certain vesting conditions.